世界中医药

目的：探讨志苓胶囊联合mFOLFOX6方案用于初治老年晚期直肠癌的临床疗效。方法：选取延安大学附属医院消化科收治的老年晚期直肠癌患者86例，随机分为观察组与对照组。对照组患者采用FOLFOX6方案进行治疗；观察组则在对照组治疗基础上同时给予志苓胶囊进行治疗。治疗后，评价2组近期疗效。对所有患者随访2年，观察其1年生存率、2年生存率、总生存时间（OS）及疾病进展时间（TTP）；观察患者治疗期间各类型不良反应。结果：近期疗效评价中，观察组总有效率为76.7%，明显高于对照组的60.5%，差异有统计学意义（P<0.05）；远期疗效评价中，观察组1年生存率与对照组基本一致，差异有统计学意义（P>0.05）；观察组2年生存率、OS及TTP分别为：62.8%、17.3个月及10.7个月，均明显高于对照组，差异有统计学意义（P<0.05）。治疗期间，观察组各项不良反应的发生率均明显低于对照组，差异有统计学意义（均P<0.05）。结论：志苓胶囊联合mFOLFOX6方案治疗初治老年晚期直肠癌疗效及安全性均较好，值得进行进一步研究。

English Summary:

To investigate the clinical efficacy of Zhiling capsule combined with mFOLFOX6 method in treating elderly advanced rectal carcinoma.Methods:A total of 86 patients with elderly advanced rectal carcinoma who were treated in our hospital were randomly divided into observation group (43 cases) and control group (43 cases).The patients of control group were treated by mFOLFOX6 method，while the patients of observation group were given Zhiling capsule based on conventional treatment of control group.The curative effects were evaluated after treatment in the two groups.The 1 year survival rate，2 year survival rate，OS and TTP were observed to evaluate the long-term effects in the two groups.The toxicity of the two groups was compared during the treatment.Results:The total effective rate of the patients in the observation group was 76.7%，which was significantly higher than the 60.5 % in the control group (P<0.05).The 2 year survival rate，OS and TTP of the patients in the observation group were 62.8%，17.3 months and 10.7 months，significantly higher than that in the control group (P<0.05).There were no serious toxicity in the two groups during the treatment，and the rates of toxicity were significantly lower in the observation group than the control group (P<0.05).Conclusion:Zhiling capsule combined with mFOLFOX6 method in the therapy of elderly advanced rectal carcinoma has good effects，which is worthy of further research.

查看全文查看/发表评论下载PDF阅读器